智通财经APP讯，成大生物(688739.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为1.23亿元至1.39亿元，与上年同期(法定披露数据)相比，将减少20,343.16万元至21,935.16万元， 同比减少59.34%至63.98%。 ...

Core Viewpoint - Chengda Biological has announced its annual performance forecast, expecting a significant decline in net profit for 2025, primarily due to reduced operating income and increased asset impairment losses [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of 123.47 million to 139.39 million yuan for 2025, representing a year-on-year decrease of 59.34% to 63.98% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 31.85 million and 47.77 million yuan, reflecting a year-on-year decline of 85.25% to 90.16% [1] Group 2: Business Impact - The decline in net profit is attributed to a decrease in operating income and an increase in asset impairment losses, primarily influenced by changes in the domestic rabies vaccine market environment [1] - Factors contributing to reduced operating income include regulatory changes, intensified market competition, and a slowdown in product sales due to inventory adjustments and procurement rhythm changes [1] Group 3: Asset Impairment and Management - The increase in asset impairment losses is mainly due to the company's strategic decision to terminate the development of the Hib vaccine project, leading to a full impairment of capitalized R&D investments [1] - Despite the challenges, the company experienced growth in overseas sales and has effectively controlled selling and administrative expenses through enhanced internal management, which has somewhat mitigated the downward pressure on performance [1] Group 4: Non-Operating Gains - The company reported an increase in non-operating gains, primarily due to the recovery in asset valuations from investments in private equity funds within the innovative drug sector, resulting in increased income [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]

三生国健(688336.SH)发布2025年年度业绩预告，预计归属于上市公司股东的净利润为29.00亿元左右， 比上年同期增长311.35%。报告期内，公司与辉瑞公司（PfizerInc.）达成重要合作；公司收到辉瑞公司 就707项目支付的授权许可首付款并相应确认收入约28.90亿元人民币，导致2025年度的营业收入、归属 于母公司所有者的净利润以及扣除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002773 | 康弘药业 | 31.45 | -3.47% | 11.24万 | 3.56亿 | | 688336 | 三生国健 | 57.27 | -2.54% | 3.35万 | 1.92亿 | | 688331 | 荣昌生物 | 100.28 | -1.95% | 6.56万 | 6.57亿 | | 688293 | 奥浦迈 | 56.09 | -1.60% | 1.11万 | 6233.60万 | | 603087 | 目李药业 | 71.68 | -1.58% | 8.23万 | 5.90 亿 | | 688278 | 特宝生物 | 74.98 | -1.19% | 2.01万 | 1.51亿 | | 688520 | 神州组胞 | 45.88 | -0.97% | 3.87万 | 1.77亿 | | 688488 | 艾迪药业 | 18.54 | -0.54% | 10.74万 | 1.98 Z | | 603590 | 康辰约业 | ...

Market Overview - On January 26, the A-share market experienced slight fluctuations after reaching resistance at 4160 points, with the Shanghai Composite Index closing at 4132.61 points, down 0.09%[7] - The total trading volume for both markets was 32,810 billion yuan, above the median of the past three years[3] Sector Performance - Financial, pharmaceutical, non-ferrous metals, and petroleum sectors performed well, while aerospace, electronic chemicals, computer equipment, and semiconductors lagged[3] - Over 60% of stocks in the two markets declined, with non-ferrous metals and precious metals leading the gains, while aerospace and semiconductor sectors saw significant outflows[7] Valuation Metrics - The average price-to-earnings (P/E) ratios for the Shanghai Composite and ChiNext indices were 16.91 times and 54.02 times, respectively, above the median levels of the past three years, indicating a suitable environment for medium to long-term investments[3][13] Investment Strategy - Investors are advised to adopt a balanced allocation strategy, focusing on AI, high-end manufacturing, and cyclical sectors, as well as resource and consumer sectors for future investment opportunities[3] - Short-term investment opportunities are recommended in the financial, pharmaceutical, petroleum, and coal industries[3] Risk Factors - Potential risks include unexpected overseas economic downturns, domestic policy changes, and macroeconomic disturbances that could impact recovery[4]

Core Viewpoint - The A-share market experienced a mixed performance with the three major indices showing a decline by the end of the trading day, indicating a cautious sentiment among investors [1]. Market Performance - The Shanghai Composite Index closed at 4132.61 points, down by 0.09%, with a total trading volume of 14,518.60 billion yuan - The Shenzhen Component Index closed at 14,316.64 points, down by 0.85%, with a total trading volume of 17,963.43 billion yuan - The ChiNext Index closed at 3319.15 points, down by 0.91%, with a total trading volume of 8,384.91 billion yuan [1]. Sector Performance - The top-performing sectors included: - Precious metals with a notable increase - Oil and gas extraction and services, which rose by 4.71% - Small metals, which increased by 4.51% [2]. - The sectors that faced declines included: - Military electronics, which dropped by 5.42% - Military equipment, down by 3.71% - Semiconductor sector, which decreased by 3.00% [2].

1月26日，A股三大股指高开低走，低位窄幅震荡，中小盘股表现疲软，截止收盘，沪指跌0.08%报 4132.9点，深成指跌0.85%报14316.64点，创业板指跌0.91%报3319.15点，科创50指数跌1.33%报1533.04 点。沪深两市合计成交额32453.25亿元，沪深两市成交额3.25万亿，全市场超3700只个股下跌。 盘面市场热点较为杂乱，有色金属板块涨幅居前，其中贵金属概念领涨，四川黄金8天4板，晓程科技、 湖南黄金、盛达资源等多股涨停，紫金矿业创历史新高；生物疫苗相关板块集体走高，华兰疫苗、之江 生物等多股封板；油气概念走强，中国海油创历史新高，洲际油气4天3板；太空光伏概念反复活跃，明 阳智能、拓日新能、协鑫集成涨停；化工板块震荡拉升，红宝丽、澄星股份涨停；商业航天板块今日走 势低迷，海格通信、神剑股份等多股跌停；半导体设备板块同样表现不佳，至纯科技封死跌停。 热点板块 生物疫苗、抗病毒、流感等医药股全线上涨，康乐卫士、迈克生物、凯普生物、之江生物、华兰疫苗等 多股涨停。 消息面上，近日，印度西孟加拉邦暴发尼帕病毒疫情，可人传人，死亡率最高达75%，尚无疫苗。据当 地媒体称，感染者在加尔 ...

据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...

Core Viewpoint - The A-share market showed mixed performance with the Shanghai Composite Index slightly up by 0.12%, while the Shenzhen Component and ChiNext indices fell by 0.74% and 0.86% respectively [1] Market Performance - As of the midday close, the Shanghai Composite Index stood at 4141.01 points, the Shenzhen Component at 14332.86 points, and the ChiNext at 3320.81 points [1] - The top-performing sectors included precious metals, oil and gas extraction and services, and industrial metals, while sectors such as military electronics, military equipment, and gaming experienced significant declines [1] Sector Performance Rankings - The top sectors by percentage increase included: - Audio and video equipment: +9.31% with a total trading volume of 925.58 million hands and a net inflow of 270.28 million [2] - Oil and gas extraction and services: +4.73% with a trading volume of 2098.10 million hands and a net inflow of 146.91 million [2] - Industrial metals: +4.02% with a trading volume of 6526.45 million hands and a net inflow of 1002.47 million [2] - The sectors with the largest declines included: - Military electronics: -4.63% with a trading volume of 1899.58 million hands and a net outflow of 74.76 million [2] - Military equipment: -2.95% with a trading volume of 2273.68 million hands and a net outflow of 83.28 million [2] - Gaming: -2.74% with a trading volume of 926.31 million hands and a net outflow of 22.32 million [2]